Incyte’s Zynyz receives FDA approval for anal cancer treatment

WILMINGTON — Incyte, one of Delaware’s top pharmaceutical companies, has secured U.S. Food and Drug Administration (FDA) approval to use Zynyz as a treatment for anal cancer.

Zynyz, an intravenous PD-1 inhibitor, may now be used in combination with platinum-based chemotherapy as well as a monotherapy for metastatic squamous cell carcinoma (SCAC), which makes up the majority of anal cancer…